1-3 of 3
Noemi Toiber Temin
Close
Sort by
Journal Articles

Analysis of the Risk of Infection Stratified By Absolute Neutrophil Counts during Deferiprone-Associated Severe Neutropenia or Agranulocytosis

Sherif M. Badawy, Jan Palmblad, Fernando Tricta, Noemi Toiber Temin, Caroline Fradette, Leo Lin, Anna Rozova, Sujit Sheth
Journal: Blood
Blood (2023) 142 (Supplement 1): 2501.
https://doi.org/10.1182/blood-2023-181963
Published: 2023
Journal Articles

Safety of Deferiprone in Patients with Myelodysplastic Syndromes: Results from the Deferiprone US Safety Registry and a Compassionate Use Program

Amer M. Zeidan, Caroline Fradette, Anna Rozova, Noemi Toiber Temin, Fernando Tricta
Journal: Blood
Blood (2022) 140 (Supplement 1): 1115–1117.
https://doi.org/10.1182/blood-2022-169074
Published: 2022
Journal Articles

Randomized Controlled Trial of the Efficacy and Safety of Deferiprone in Iron-Overloaded Patients with Sickle Cell Disease or Other Anemias

Janet L. Kwiatkowski, MD MSCE, Mohsen Saleh Elalfy, MD, Caroline Fradette, PhD, Mona Hamdy, MD, Amal El-Beshlawy, MD, Fatma Soliman Elsayed Ebeid, MD, Monica PINHEIRO DE ALMEIDA Verissimo, MD, Mohamed Ahmed Badr, MD, Alshehri Abdulrahman, MD, Julie Kanter, MD, Baba PD Inusa, MD, Mohamed Bejaoui, MD, Suzan Williams, MD, Yurdanur Kilinc, MD, Yu-Chung Tsang, PhD, Anne Stilman, BA, Anna Rozova, MD, Jodie Sinclair, MSc, Dian Shaw, RN, Theresa Chan, BSc, Noemi Toiber Temin, MA, David Lee, PhD, Michael Spino, PharmD, Fernando Tricta, MD
Journal: Blood
Blood (2019) 134 (Supplement_1): 618.
https://doi.org/10.1182/blood-2019-122062
Published: 2019